Evidence map›Paper›PMID 36254554›Full record

ArticleTechnology in cancer research & treatment

Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo.

Xiupeng Ye, Meijing Liu, Cuicui Lv, Yeqiong Li, Lan Chen, Jin Zhang, Juan Mu, Qi Deng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. The magic of small-molecule drugs duringFrontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiupeng Ye159438People's Hospital of Ningxia Hui Autonomous Region, Yinchuan City, China.ORCID 0000-0003-3087-3956
Meijing LiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, 74566The First Affiliated Hospital of Soochow University, Suzhou, China.
Cuicui LvDepartment of Hematology, 66571Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yeqiong Li159438People's Hospital of Ningxia Hui Autonomous Region, Yinchuan City, China.
Lan Chen159438People's Hospital of Ningxia Hui Autonomous Region, Yinchuan City, China.
Jin Zhang159438People's Hospital of Ningxia Hui Autonomous Region, Yinchuan City, China.
Juan MuDepartment of Hematology, 66571Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Qi DengDepartment of Hematology, 66571Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Nankai University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Programmed Cell Death 1 ReceptorReceptors, Chimeric AntigenAnimalsMicePiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesT-LymphocytesPiperidinesProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsPyrazolesPyrimidinesReceptors, Chimeric AntigenzanubrutinibBruton tyrosine kinasechimeric antigen receptor T-celllymphomazanubrutinib

Identifiers

PMID36254554
PMCPMC9580088
OpenAlexW4306729379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.